Author: OurCrowd

[Edity Therapeutics in WebWire] Edity Therapeutics enters into a strategic co-development partnership with Aurigene Oncology to advance a novel cell therapy program for solid tumors

Edity Therapeutics and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited, a clinical-stage biotechnology company, announced a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors. Read...

Read More